ACST Acasti Pharma Inc.

1.32
+0.03  (2%)
Previous Close 1.29
Open 1.28
Price To book 1.22
Market Cap 19424912
Shares 14,735,937
Volume 43,539
Short Ratio 0.04
Av. Daily Volume 20,173

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated 2H 2017.
CaPre
Hypertriglyceridemia

Latest News

  1. Acasti Pharma Grants Stock Options
  2. Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM
  3. Acasti reports 1Q loss
  4. Acasti Pharma Reports First Quarter FY 2018 Financial Results
  5. Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures
  6. CORRECTION: Acasti Pharma Grants Stock Options
  7. Acasti Pharma To Present at Upcoming International Industry Conferences
  8. Acasti Pharma Reports Fourth Quarter and Full-Year 2017 Financial Results
  9. Acasti Pharma and CordenPharma Announce Large Scale Production of CaPre® with New Continuous Manufacturing Process
  10. Acasti Pharma Presents CaPre Clinical Data at National Lipid Association Scientific Sessions
  11. Acasti Granted Additional Composition & Use Patents in Taiwan and Australia; Safeguards Valuable Market Expansion Opportunities
  12. Acasti Pharma to Present CaPre Omega-3 Bridging Study Results at National Lipid Association Scientific Sessions
  13. Acasti Pharma Provides Update On CaPre Phase 3 Development Program
  14. Acasti Pharma Forms Scientific Advisory Board and Appoints Two Leading Cardiovascular Disease Experts
  15. Acasti Pharma Grants Incentive Stock and Options
  16. Acasti Pharma Announces Proposed Private Placement of Convertible Debentures and Amended Proposed Offering of Units
  17. Biotech Industry a Focus in 2017: Latest Reports on Nektar Therapeutics and Acasti Pharma
  18. Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q3, 2017 By the Numbers : January 16, 2017